Equities analysts forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce $4.53 billion in sales for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings. The lowest sales estimate is $4.41 billion and the highest is $4.76 billion. Teva Pharmaceutical Industries reported sales of $5.46 billion in the same quarter last year, which indicates a negative year over year growth rate of 17%. The company is scheduled to report its next quarterly earnings results on Thursday, February 14th.
On average, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $18.85 billion for the current financial year, with estimates ranging from $18.71 billion to $19.05 billion. For the next fiscal year, analysts forecast that the company will post sales of $17.89 billion, with estimates ranging from $17.22 billion to $18.15 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. During the same quarter in the prior year, the business earned $1.00 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was down 19.4% on a year-over-year basis.
TEVA stock traded down $0.39 during trading on Monday, hitting $23.45. 6,637,061 shares of the company’s stock traded hands, compared to its average volume of 10,918,274. Teva Pharmaceutical Industries has a 52 week low of $11.44 and a 52 week high of $25.96. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $24.13 billion, a P/E ratio of 7.39, a price-to-earnings-growth ratio of 7.28 and a beta of 0.77.
In other news, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the sale, the vice president now owns 2,488 shares in the company, valued at approximately $58,940.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. Insiders sold a total of 6,531 shares of company stock valued at $152,749 in the last 90 days. Company insiders own 0.43% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. CIBC World Markets Inc. increased its stake in Teva Pharmaceutical Industries by 9.6% in the 3rd quarter. CIBC World Markets Inc. now owns 536,143 shares of the company’s stock worth $11,549,000 after buying an additional 46,887 shares during the period. FMR LLC increased its stake in Teva Pharmaceutical Industries by 19.1% in the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after buying an additional 3,921,785 shares during the period. Polaris Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 9.0% in the 3rd quarter. Polaris Capital Management LLC now owns 9,911,038 shares of the company’s stock worth $213,484,000 after buying an additional 817,964 shares during the period. Fosun International Ltd increased its stake in Teva Pharmaceutical Industries by 36.5% in the 3rd quarter. Fosun International Ltd now owns 43,000 shares of the company’s stock worth $909,000 after buying an additional 11,500 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Teva Pharmaceutical Industries by 11.4% in the 3rd quarter. Janus Henderson Group PLC now owns 141,421 shares of the company’s stock worth $3,047,000 after buying an additional 14,500 shares during the period. Hedge funds and other institutional investors own 65.10% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.